Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Anavex Lf SC
(NQ:
AVXL
)
3.810
-0.070 (-1.80%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Anavex Lf SC
< Previous
1
2
3
4
5
6
7
8
Next >
40 Stocks Moving In Monday's Mid-Day Session
June 14, 2021
Gainers Enochian Biosciences, Inc. (NASDAQ: ENOB) shares jumped 127.2% to $10.02. The FDA has accepted Enochian BioSciences Inc's pre-IND (Investigational New Drug) request...
Via
Benzinga
Exposures
Product Safety
Anavex Life Sciences' Alzheimer's Candidate Mechanism Of Action Explained In Medical Journal
June 14, 2021
Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that ANAVEX 2-73 (blarcamesine) and ANAVEX3-71 (AF710B) are featured in a new peer-reviewed publication in...
Via
Benzinga
Biotechs Ready To Roar
June 13, 2021
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...
Via
Talk Markets
Exposures
Product Safety
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
June 08, 2021
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure.
Via
Investor's Business Daily
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
June 07, 2021
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision.
Via
Investor's Business Daily
Exposures
Product Safety
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks
May 21, 2021
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too.
Via
Investor's Business Daily
Exposures
Product Safety
Anavex Life Sciences (AVXL) Q2 2021 Earnings Call Transcript
May 14, 2021
AVXL earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
May 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
Alzheimer's Disease: 5 Stocks on Biotech Radars
April 22, 2021
What's been interesting for the past couple of years, and especially the last few months, is to watch the rise of emerging, small-cap Biotech companies trying to take on the big AD and other...
Via
Talk Markets
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
April 20, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
COVID-19
Death
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.